SEC Comment Letter 0000000000-24-009221 to Corvus Pharmaceuticals, Inc. (CRVS) (CIK 0001626971) (CRVS)
Corvus Pharmaceuticals, Inc. (CRVS) (CIK 0001626971)
Date: Aug. 13, 2024 · CIK: 0001626971 · Accession: 0000000000-24-009221
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281318
Letter
August 13, 2024 Richard A. Miller, M.D. Chief Executive Officer Corvus Pharmaceuticals, Inc. 863 Mitten Road, Suite 102 Burlingame, CA 94010 Re:Corvus Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 6, 2024 File No. 333-281318 Dear Richard A. Miller, M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Phillip Stoup
Show Raw Text
August 13, 2024
Richard A. Miller, M.D.
Chief Executive Officer
Corvus Pharmaceuticals, Inc.
863 Mitten Road, Suite 102
Burlingame, CA 94010
Re:Corvus Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed August 6, 2024
File No. 333-281318
Dear Richard A. Miller, M.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Phillip Stoup